MX2024003974A - Fármaco para el tratamiento del hígado graso y la esteatohepatitis no alcohólica. - Google Patents
Fármaco para el tratamiento del hígado graso y la esteatohepatitis no alcohólica.Info
- Publication number
- MX2024003974A MX2024003974A MX2024003974A MX2024003974A MX2024003974A MX 2024003974 A MX2024003974 A MX 2024003974A MX 2024003974 A MX2024003974 A MX 2024003974A MX 2024003974 A MX2024003974 A MX 2024003974A MX 2024003974 A MX2024003974 A MX 2024003974A
- Authority
- MX
- Mexico
- Prior art keywords
- fatty liver
- drug
- alcoholic
- steathepatitis
- treatment
- Prior art date
Links
- 208000004930 Fatty Liver Diseases 0.000 title abstract 3
- 206010019708 Hepatic steatosis Diseases 0.000 title abstract 3
- 208000010706 fatty liver disease Diseases 0.000 title abstract 3
- 231100000240 steatosis hepatitis Toxicity 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 abstract 2
- 102000055207 HMGB1 Human genes 0.000 abstract 2
- 108700010013 HMGB1 Proteins 0.000 abstract 2
- 101150021904 HMGB1 gene Proteins 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2021/036238 WO2023053384A1 (ja) | 2021-09-30 | 2021-09-30 | 脂肪肝および非アルコール性脂肪肝炎の治療薬 |
| PCT/JP2022/036662 WO2023054666A1 (ja) | 2021-09-30 | 2022-09-30 | 脂肪肝および非アルコール性脂肪肝炎の治療薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003974A true MX2024003974A (es) | 2024-07-09 |
Family
ID=85781770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003974A MX2024003974A (es) | 2021-09-30 | 2022-09-30 | Fármaco para el tratamiento del hígado graso y la esteatohepatitis no alcohólica. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240299496A1 (https=) |
| EP (1) | EP4410302A4 (https=) |
| JP (1) | JP7798300B2 (https=) |
| KR (1) | KR20240070640A (https=) |
| CN (1) | CN118317780A (https=) |
| AU (1) | AU2021466375A1 (https=) |
| CA (1) | CA3233234A1 (https=) |
| MX (1) | MX2024003974A (https=) |
| WO (2) | WO2023053384A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3358011T (pt) | 2011-04-26 | 2020-04-23 | Univ Osaka | Péptido para induzir a regeneração de um tecido e a sua utilização |
| US20200038486A1 (en) | 2017-04-07 | 2020-02-06 | StemRIM Inc. | Therapeutic medicine for fibrous disease |
| EP3728593A1 (en) * | 2017-12-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
-
2021
- 2021-09-30 AU AU2021466375A patent/AU2021466375A1/en active Pending
- 2021-09-30 CA CA3233234A patent/CA3233234A1/en active Pending
- 2021-09-30 WO PCT/JP2021/036238 patent/WO2023053384A1/ja not_active Ceased
- 2021-09-30 KR KR1020247014019A patent/KR20240070640A/ko active Pending
- 2021-09-30 JP JP2023550943A patent/JP7798300B2/ja active Active
-
2022
- 2022-09-30 MX MX2024003974A patent/MX2024003974A/es unknown
- 2022-09-30 EP EP22876529.3A patent/EP4410302A4/en active Pending
- 2022-09-30 WO PCT/JP2022/036662 patent/WO2023054666A1/ja not_active Ceased
- 2022-09-30 CN CN202280078804.6A patent/CN118317780A/zh active Pending
- 2022-09-30 US US18/697,330 patent/US20240299496A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240299496A1 (en) | 2024-09-12 |
| EP4410302A1 (en) | 2024-08-07 |
| EP4410302A4 (en) | 2025-07-23 |
| AU2021466375A1 (en) | 2024-04-11 |
| KR20240070640A (ko) | 2024-05-21 |
| CA3233234A1 (en) | 2023-04-06 |
| WO2023054666A1 (ja) | 2023-04-06 |
| CN118317780A (zh) | 2024-07-09 |
| JPWO2023053384A1 (https=) | 2023-04-06 |
| WO2023053384A1 (ja) | 2023-04-06 |
| JP7798300B2 (ja) | 2026-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002099A1 (es) | Combinación farmacéutica que comprende tno155 y ribociclib. | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| BR112022005896A2 (pt) | Inibidores da mek para o tratamento de infecções causadas por hantavírus | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2019001411A1 (es) | Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817) | |
| CO2021001472A2 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
| EA202190377A1 (ru) | Композиции ингибиторов cxcr4 и способы получения и применения | |
| EA202091964A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| CR20230100A (es) | Compuestos fosfolípidos y usos de los mismos | |
| DOP2025000244A (es) | Compuestos y métodos para el tratamiento de infecciones virales | |
| CL2023001062A1 (es) | Compuestos fosfolípidos y usos de estos | |
| CL2019000228A1 (es) | Tratamiento conjunto contra tipos de cáncer hematológico. | |
| MX2018004132A (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
| CO2025003733A2 (es) | Compuestos cíclicos de urea tiazolilo para el tratamiento del hsv | |
| EA202192101A1 (ru) | Соединения и их применение | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CL2022000091A1 (es) | Métodos para tratar la pancreatitis. (divisional de solicitud n° 202100585) | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| MX2020003943A (es) | Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. | |
| CL2020000859A1 (es) | Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas. | |
| MX2022011845A (es) | Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| EA202090424A1 (ru) | Бициклические ингибиторы гистондеацетилазы | |
| MX2024003974A (es) | Fármaco para el tratamiento del hígado graso y la esteatohepatitis no alcohólica. |